Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 11/20 | 1.00 |
| ▸ | BTK | Q06187 | 7/20 | 0.75 |
| ▸ | EGFR | P00533 | 9/20 | 0.72 |
| ▸ | JAK2 | O60674 | 2/20 | 0.72 |
| ▸ | JAK1 | P23458 | 1/20 | 0.72 |
| ▸ | TYK2 | P29597 | 1/20 | 0.72 |
| ▸ | FLT3 | P36888 | 5/20 | 0.71 |
| ▸ | BLK | P51451 | 5/20 | 0.65 |
| ▸ | BMX | P51813 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17209892 | 0.88 | JAK3 (1.00) | JAK3BTKEGFRJAK2JAK1 | |
| SCHEMBL21846866 | 0.86 | JAK3 (0.75) | JAK3BTKEGFRJAK2JAK1 | |
| SCHEMBL18000678 | 0.86 | BTK (1.00) | JAK3BTKEGFRJAK2JAK1 | |
| SCHEMBL21846862 | 0.85 | JAK3 (0.78) | JAK3BTKEGFRJAK2JAK1 | |
| SCHEMBL29388091 | 0.85 | JAK3 (0.78) | JAK3BTKEGFRJAK2JAK1 | |
| SCHEMBL16680413 | 0.83 | FLT3 (1.00) | JAK3BTKEGFRFLT3BLK | |
| SCHEMBL28583057 | 0.81 | EGFR (0.80) | JAK3BTKEGFRJAK2JAK1 | |
| SCHEMBL17209811 | 0.80 | JAK3 (1.00) | JAK3BTKEGFRJAK2JAK1 | |
| SCHEMBL17209826 | 0.80 | JAK3 (1.00) | JAK3BTKEGFRJAK2JAK1 | |
| SCHEMBL17210135 | 0.80 | JAK3 (1.00) | JAK3BTKEGFRJAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220048914-A1 | PREPARATION FOR 6-AMINO-1H-PYRAZOLO[3,4-D]PYRIMIDINE-BASED JAK KINASE INHIBITOR AND APPLICATION THEREOF | CHINA PHARMACEUTICAL UNIVERSITY (CN) | 2022-02-17 | — | — | US | disclosed |
| WO-2020052489-A1 | PREPARATION FOR 6-AMINO-1H-PYRAZOLO[3,4-D]PYRIMIDINE-BASED JAK KINASE INHIBITOR AND APPLICATION THEREOF | 中国药科大学 | 2020-03-19 | — | — | WO | disclosed |
| US-10017477-B2 | Janus kinase inhibitors and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-07-10 | — | — | US | disclosed |
| US-20170044111-A1 | JANUS KINASE INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-02-16 | — | — | US | disclosed |
| WO-2015164614-A1 | JANUS KINASE INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2015-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170044111-A1 | JANUS KINASE INHIBITORS AND USES THEREOF | JAK3, JAK1, JAK2 | JAK3 1/4885BTK 49/4885EGFR 692/4885 |
| US-10017477-B2 | Janus kinase inhibitors and uses thereof | JAK3, JAK1, JAK2 | JAK3 1/4885BTK 49/4885EGFR 692/4885 |
| US-20220048914-A1 | PREPARATION FOR 6-AMINO-1H-PYRAZOLO[3,4-D]PYRIMIDINE-BASED JAK KINASE INHIBITOR AND APPLICATION THEREOF | JAK1, JAK3, SSB | JAK3 2/4885BTK 8/4885EGFR 2648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.